Andere talen CANbridge Pharmaceuticals Inc.

Aandelen

1228

KYG1821D1097

Vertraagde tijd Hong Kong S.E. Andere beurzen 07:12:17 26-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
0,455 ^HKD	+3,41%		+42,19%	-54,04%

28/03	CANbridge Pharmaceuticals Inc. rapporteert resultaten voor het volledige jaar dat eindigde op 31 december 2023	CI
2023	CANbridge Pharmaceuticals Inc. kondigt aan dat Derek Paul Di Rocco ontslag heeft genomen als niet-uitvoerend bestuurder en lid van het Comité voor Benoemingen en Corporate Governance	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Canbridge Pharmaceuticals Shelves Glioblastoma Drug After Phase II Clinical Trials	23/04
CANbridge Pharmaceuticals Inc. Announces Change of Principal Place of Business in Hong Kong, Effect from April 15, 2024	12/04
CANbridge Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28/03
CANbridge and PUMCH announced the establishment of PUMCH, CANbridge Genetic Defect Rare Disease Innovation and Translation Base	04/03
CANbridge Pharmaceuticals Grants Share Options, Restricted Shares	08/02
CANbridge Pharmaceuticals Inc. Announces Resignation of Derek Paul Di Rocco as Non-Executive Director and A Member of the Nomination and Corporate Governance Committee	23/11
CANbridge Pharmaceuticals - Foundation consolidated over time and for a rosy future, 2023 China Conference on Rare Diseases closed successfully	07/11
CANbridge Pharmaceuticals to Present Fabry Disease Gene Therapy Abstract at ESGCT 30th Annual Congress	26-10-23
CANbridge Pharmaceuticals Inc. to Present Fabry Disease Gene Therapy Abstract At Esgct 30Th Annual Congress	25-10-23
CANbridge Announces NDA Acceptance of CAN108 for Cholestatic Pruritus in Progressive Familial Intrahepatic Cholestasis by China's National Medical Products Administration	18-10-23
CANbridge Announces NDA Acceptance of CAN108 (®/LIVMARLI®) for Cholestatic Pruritus in Progressive Familial Intrahepatic Cholestasis by China's National Medical Products Administration	17-10-23
CANbridge Announces Full Enrollment Reached in the Core Part of the CAN103 Phase 2 trial for Gaucher Disease in China	16-10-23
Canbridge Pharmaceuticals Inc. Announces Full Enrollment Reached in the Core Part of the Can103 Phase 2 Trial for Gaucher Disease in China	16-10-23
CANbridge Announces Marketing Approval of CAN108 in Taiwan for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome	09-10-23
Canbridge Pharmaceuticals Inc. Announces Marketing Approval of Can108 (Maralixibat Chloride Oral Solution /Livmarli®?) in Taiwan for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome	09-10-23
CANbridge to Participate in Two Investor Conferences in September	07-09-23
CANbridge Pharmaceuticals' H1 Attributable Loss Narrows	31-08-23
CANbridge Pharmaceuticals Inc. Reports Earnings Results for the Half Year Ended June 30, 2023	31-08-23
CANbridge Pharmaceuticals Releases Phase 1B Data for Red Blood Cell Disorder Treatment	26-06-23
CANbridge Pharmaceuticals Inc. Announces Preliminary Clinical Data of Phase 1B Study of Omoprubart in Paroxysmal Nocturnal Hemoglobinuria	26-06-23

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen CANbridge Pharmaceuticals Inc.

Aandelen

1228

KYG1821D1097

Andere talen

Filters